title: Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
abstract: Cancer treatment that uses a combination of approaches with the ability to affect multiple disease pathways has been proven highly effective in the treatment of many cancers. Combination therapy can include multiple chemotherapeutics or combinations of chemotherapeutics with other treatment modalities like surgery or radiation. However, despite the widespread clinical use of combination therapies, relatively little attention has been given to the potential of modern nanocarrier delivery methods, like liposomes, micelles, and nanoparticles, to enhance the efficacy of combination treatments. This lack of knowledge is particularly notable in the limited success of vectors for the delivery of combinations of nucleic acids with traditional small molecule drugs. The delivery of drug-nucleic acid combinations is particularly challenging due to differences in the physicochemical properties of the two types of agents. This review discusses recent advances in the development of delivery methods using combinations of small molecule drugs and nucleic acid therapeutics to treat cancer. This review primarily focuses on the rationale used for selecting appropriate drug-nucleic acid combinations as well as progress in the development of nanocarriers suitable for simultaneous delivery of drug-nucleic acid combinations.
authors.affiliation: Department of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198-5830, USA.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhu
authors.forename: David
authors.initials: D
authors.lastname: Oupický
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D049329:Nanostructures / Q000737:chemistry; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009696:Nucleic Acids / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D009696:Nucleic Acids
keywords: 5-FU; 5-fluorouracil; AAV-2; AON; ASCL1; BENSpm; CXCL12; CXCR4 cognate ligand SDF-1; CYP3A; Cancer treatment; Combination therapy; DOPE; DOX; Drug delivery; EGFR; Gene delivery; HA; HNSCC; IL-12; IL-24; MDR; MDR1; MSN; MVP; Multifunctional nanocarriers; N(1),N(11)-bisethylnorspermine; NFκB; P-glycoprotein; PAMAM; PEI; PLGA; PTX; Pgp; QDs; TMZ; TNF-α; TRAIL; VEGF; achaete–scute complex-like 1; adeno-associated virus-2; antisense oligonucleotides; cytochrome P450 3A; dioleoylphosphatidylethanolamine; doxorubicin; epidermal growth factor receptor; head and neck squamous cell carcinoma; hyaluronic acid; interleukin-12; interleukin-24; major vault protein; mesoporous silica nanoparticles; multidrug resistance; multidrug resistance protein 1; nuclear factor kappa-light-chain-enhancer of activated B cells; pDNA; pERK; paclitaxel; phosphorylated extracellular signal-regulated kinase; plasmid DNA; poly(d,l-lactide-co-glycolide); polyamidoamine; polyethylenimine; quantum dots; shRNA; siRNA; siRNA delivery; small hairpin RNA; small interfering RNA; temozolomide; tumor necrosis factor-alpha; tumor necrosis factor-related apoptosis-inducing ligand; vascular endothelial growth factor; β-CD; β-cyclodextrin